NewAmsterdam Pharma Appoints Industry Leader Adele Gulfo To Board Of Directors

NewAmsterdam Pharma, a late-stage clinical biopharmaceutical company focused on developing oral, non-statin treatments for patients with high LDL-C and cardiovascular risks. The firm has announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms.Gulfo brings experience from the healthcare and pharmaceutical industries, having led commercialisation efforts for major drugs such as LIPITOR® and CRESTOR®.

“We are delighted to welcome Adele to our Board of Directors at a critical juncture for NewAmsterdam, as we prepare for the potential launch of obicetrapib next year. Adele brings world-class commercial leadership and an exceptional track record of successfully launching blockbuster therapies on a global scale. Her strategic insight, mass-market drug launch experience and deep operational expertise will be instrumental as we work diligently to finalise our commercial strategy and build the infrastructure to support our first commercial launch, if approved,” commented Michael Davidson, M.D., Ph.D., Chief Executive Officer of NewAmsterdam Pharma.

Gulfo recently held leadership roles at Sumitomo Pharma America, where she served as CEO of the Biopharma Commercial Unit, overseeing a wide-ranging portfolio in fields like oncology, rare diseases, and neurology. Her previous roles include Chief Commercial and Business Development Officer at Sumitovant Biopharma and Chief Commercial Development Officer at Roivant Sciences, where she played an integral role in the formation of Sumitovant and the launch of major brands like ORGOVYX® and MYFEMBREE®. Her earlier tenure at Pfizer included overseeing its U.S. primary care business and leading the successful launch of LIPITOR®, while at AstraZeneca, she spearheaded the commercial growth of CRESTOR®.

“I am thrilled to join NewAmsterdam Pharma’s Board of Directors at a transformational time for the Company. NewAmsterdam Pharma’s progress is impressive, with successful execution and recent positive readouts from its three pivotal Phase 3 clinical trials. I believe NewAmsterdam is well on the path to making a significant impact on the treatment paradigm for patients at risk of CVD, and I look forward to partnering with the Board and executive leadership team as we drive forward the company's mission to improve the standard of care for CVD patients worldwide” said Ms. Gulfo. 

In addition to her executive position, Ms.Gulfo is a board member at Tyra Biosciences and Enpro and belongs to the Innovation Growth Board at Mass General Brigham. She holds a biology degree from Seton Hall University before accomplishing her MBA with distinction from Fairleigh Dickinson University.